Q-omics provides the consensus-scored NFXL1 profile across patient tissues and cancer cell-line models. NFXL1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, NFXL1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, NFXL1 RNA expression shows 21,205 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight READ, COAD, and ACC as cancer lineages where NFXL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NFXL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NFXL1 survival associations across molecular data types. NFXL1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NFXL1 RNA expression–survival associations across cancer types. High NFXL1 expression shows unfavorable associations in LIHC, ACC, KICH and SARC, but favorable associations in READ and KIRC. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for NFXL1 RNA expression.
This table summarizes NFXL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NFXL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NFXL1 shows lower tumor expression in THCA and higher tumor expression in COAD, LUAD, LIHC, STAD and BLCA. The COAD box plot shows higher NFXL1 RNA expression in tumor versus normal tissue (log2 FC = +1.302, t-test p < 0.001).
This table shows molecular features associated with NFXL1 in patient tissues and cancer cell lines. In patient samples, NFXL1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NFXL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
